Clear cell renal carcinoma

This early-stage trial is testing an experimental therapy called HS-IT101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. The treatment involves collecting immune cells from the patient's tumor, multiplying them in the lab, and infusing them bac…

Researchers are testing a radiopharmaceutical called 161Tb-PSMA-1 in adults with metastatic clear cell renal cell carcinoma that has worsened after at least two prior treatments, including immunotherapy and drugs that block blood vessel growth. The trial has two parts: a dose-esc…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…

This phase II trial is testing whether giving toripalimab (an immunotherapy) plus axitinib (a targeted therapy) for about 12 weeks before a possible delayed kidney removal can help control advanced clear cell kidney cancer. The study enrolls adults whose primary kidney tumor is s…

This trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…

This phase 2 trial is testing whether a combination of two drugs—zanzalintinib (a pill taken daily) and pembrolizumab (given by IV every three weeks)—can shrink advanced kidney tumors before surgery and help prevent the cancer from coming back afterward. The study enrolls people …

This study tests whether giving focused radiation or surgery to all visible tumors (both the original kidney tumor and its metastases) can allow people with advanced kidney cancer to stop all cancer treatments for at least a year. Participants must have stable or partially improv…

This study tests whether adding the cholesterol drug atorvastatin to standard targeted therapy (axitinib) and immunotherapy (toripalimab) can help people with advanced kidney cancer who are not responding well to treatment. The drug combination is guided by lab tests on patient-d…

This phase 2 trial tests whether adding a probiotic capsule (MO-03) to the drug zanzalintinib can help treat metastatic kidney cancer that has worsened after immunotherapy. About 34 adults with advanced clear cell renal cell carcinoma will receive both treatments. The goal is to …

This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…

This early study tests a new cell therapy called UCL70805F in 21 people with advanced clear cell kidney cancer that has not responded to standard treatments. The therapy uses immune cells designed to target a protein called CD70 on cancer cells. The main goals are to check safety…

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can help people with advanced kidney cancer (clear cell type) whose cancer returned after prior immunotherapy. About 108 adults will receive the combination to see if it shrinks tumors or delays cancer gr…

This phase 3 trial tests a radioactive drug called Lu-177 PSMA in 20 people with metastatic clear cell kidney cancer that has worsened after at least two prior treatments. The drug is designed to seek out and destroy cancer cells while limiting damage to healthy tissue. Researche…

This study looks at whether getting standard immunotherapy drugs (nivolumab and ipilimumab) in the morning or afternoon makes a difference for people with advanced kidney cancer. About 142 adults will be randomly assigned to morning or afternoon infusions. Researchers will track …

This clinical trial is for adults with metastatic clear cell kidney cancer. It compares having surgery to remove the kidney tumor either before or after starting immunotherapy drugs (ipilimumab and nivolumab). The goal is to see which timing helps people live longer without the c…

This phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if…

This phase 2 trial tests a new drug called JS004, a BTLA antibody, combined with toripalimab (an immunotherapy) in 31 people with advanced kidney cancer that has worsened after prior immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progressio…

This study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to…

This early-phase study tests a new imaging agent called RYZ512 in 10 people with advanced clear cell kidney cancer that has spread. The agent is designed to attach to a protein (CAIX) found on these cancer cells, making them show up on scans. The goal is to see if it is safe and …

This pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…